Pharmacologically targeting fatty acid synthase-mediated de novo lipogenesis alleviates osteolytic bone loss by directly inhibiting osteoclastogenesis through suppression of STAT3 palmitoylation and ROS signalingChunmei Xiu, Jianquan Chen, Chenxi Zhang et al.|Metabolism|2025Cited by 15